WallStreetZenWallStreetZen

NASDAQ: XBIT
Xbiotech Inc Stock

Open Broker Account
$3.19+0.02 (+0.63%)
Updated Dec 9, 2022
XBIT Price
$3.19
Fair Value Price
$8.47
Market Cap
$97.10M
52 Week Low
$3.00
52 Week High
$12.51
P/E
-2.68x
P/B
0.4x
P/S
13.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.21M
Earnings
-$36.16M
Gross Margin
79.5%
Operating Margin
-470.54%
Profit Margin
-440.5%
Debt to Equity
0.03
Operating Cash Flow
-$19M
Beta
0.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XBIT Overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XBIT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XBIT ($3.19) is undervalued by 62.32% relative to our estimate of its Fair Value price of $8.47 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XBIT ($3.19) is significantly undervalued by 62.32% relative to our estimate of its Fair Value price of $8.47 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XBIT due diligence checks available for Premium users.

Be the first to know about important XBIT news, forecast changes, insider trades & much more!

XBIT News

Valuation

XBIT fair value

Fair Value of XBIT stock based on Discounted Cash Flow (DCF)
Price
$3.19
Fair Value
$8.47
Undervalued by
62.32%
XBIT ($3.19) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XBIT ($3.19) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XBIT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XBIT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.68x
Industry
13.17x
Market
21.21x

XBIT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.4x
Industry
4.91x
XBIT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XBIT's financial health

Profit margin

Revenue
$1.7M
Net Income
-$12.7M
Profit Margin
-753.5%
XBIT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XBIT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$250.8M
Liabilities
$6.0M
Debt to equity
0.03
XBIT's short-term assets ($223.43M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XBIT's short-term assets ($223.43M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XBIT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XBIT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.0M
Investing
-$59.7M
Financing
$0.0
XBIT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XBIT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XBIT$97.10M+0.63%-2.68x0.40x
PRAX$98.01M+0.97%-0.41x0.93x
CAPR$96.17M-6.39%-3.37x6.23x
ONCY$98.57M-1.74%-5.38x4.76x
OLMA$98.71M-1.61%-0.97x0.45x

Xbiotech Stock FAQ

What is Xbiotech's quote symbol?

NASDAQ: XBIT) Xbiotech trades on the NASDAQ under the ticker symbol XBIT. Xbiotech stock quotes can also be displayed as NASDAQ: XBIT.

If you're new to stock investing, here's how to buy Xbiotech stock.

What is the 52 week high and low for Xbiotech (NASDAQ: XBIT)?

(NASDAQ: XBIT) Xbiotech's 52-week high was $12.51, and its 52-week low was $3.00. It is currently -74.5% from its 52-week high and 6.33% from its 52-week low.

How much is Xbiotech stock worth today?

(NASDAQ: XBIT) Xbiotech currently has 30,439,277 outstanding shares. With Xbiotech stock trading at $3.19 per share, the total value of Xbiotech stock (market capitalization) is $97.10M.

Xbiotech stock was originally listed at a price of $23.25 in Apr 15, 2015. If you had invested in Xbiotech stock at $23.25, your return over the last 7 years would have been -86.28%, for an annualized return of -24.7% (not including any dividends or dividend reinvestments).

How much is Xbiotech's stock price per share?

(NASDAQ: XBIT) Xbiotech stock price per share is $3.19 today (as of Dec 9, 2022).

What is Xbiotech's Market Cap?

(NASDAQ: XBIT) Xbiotech's market cap is $97.10M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xbiotech's market cap is calculated by multiplying XBIT's current stock price of $3.19 by XBIT's total outstanding shares of 30,439,277.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.